Physician profile
Jonathan H Engman
NPI 1649242918
$847.22
in general payments reported to CMS, 2019-2025
12 companies · $61.38 in 2025
The $61.38 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $14.98 · 2021: $114 · 2022: $99.51 · 2023: $50.20 · 2024: $318 · 2025: $61.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $402.14 | 2019-2025 | Centurion, Rocklatan, Argos |
| Johnson & Johnson Surgical Vision, INC. | $144.20 | 2024 | Tecnis Simplicity |
| Allergan, INC. | $142.23 | 2019 | |
| Sight Sciences, INC. | $35.43 | 2022 | |
| The Cameron-Ehlen Group, INC. | $18.65 | 2023 | Tecnis Iol, Healon Pro, Tecnis Simplicity |
| Mallinckrodt Enterprises LLC | $17.77 | 2019 | |
| Thea Pharma INC. | $17.26 | 2024 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $15.77 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $14.11 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $13.93 | 2022 | |
| Ocular Therapeutix, INC. | $13.78 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Engman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.